Incannex net loss narrows 59% to $19.3 million in FY26; revenue falls to no revenue

• Incannex posted a net loss of USD 19.3 million for fiscal 2026, narrowing 58% from USD 46.89 million a year earlier.
• Operating loss was USD 23.03 million, improving 3% year over year, while total operating expenses edged down 4% to USD 23.03 million.
• R&D expense fell 52% to USD 5.21 million, and G&A expense rose 36% to USD 17.82 million.
• Other income swung to USD 3.73 million from a USD 23.1 million expense, while R&D tax incentive rose 165% to USD 4.66 million.
• Cash and cash equivalents totaled USD 67.7 million at June 30, 2026, up from USD 15 million a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-063506), on September 25, 2026, and is solely responsible for the information contained therein.